Pancreatic Cancer Action Network Adaptive Clinical Trial Adds New Investigational Treatment and Additional Sites - Pancreatic Cancer Action Network
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies - The Lancet
B2 novartis | PDF
AI and 10 seconds of voice can screen for diabetes, new Mayo Clinic journal study reveals - PharmaLive
Emirates Dermatology Society And Novartis Launch 'Skin To Live In' A Groundbreaking Campaign For People Living With Psoriasis - Health Magazine
Novartis to pay $370 million to settle claims it paid kickbacks for drug referrals | Healthcare Finance News
Inclisiran Reduced LDL-C in Obese Patients | DAIC
Amidst Novartis Takeover Rumors, The Medicines Company Announces Positive Cholesterol Data | BioSpace
Bayer acquires AskBio; Novartis' Iptacopan; Forma's AML Therapy
Anumana and Novartis Collaborate To Deploy AI That Detects Heart Disease
CGRP monoclonal antibodies : summary and effectiveness - Migraine Canada™
Novartis, Sandoz recall 12 medications over packaging concerns | Fox 8 Cleveland WJW
Eclipse and Mayo Clinic create Nucleus RadioPharma to better serve cancer patients - Mayo Clinic News Network
Novartis links up with Mayo Clinic spinout Anumana to develop ECG-reading AI
30 Novartis ideas | multiple sclerosis awareness, tuberous sclerosis, oncology nursing
Plasma neurodegeneration biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological disorders | Nature Communications
Novartis taps Ada Health's AI diagnosis platform for tracking rare, immunological conditions | Fierce Biotech
The Safety of a Plant-Based Nutraceutical for Behaviour in Cats and Dogs
Lilly-Incyte drug reduces eczema symptoms in treatment-resistant patients | S&P Global Market Intelligence
Cerulean, Novartis ink $5m deal to co-develop nanoparticle-drug conjugates - Drug Delivery Business
Q&A: Is it a migraine? Many don't realize what causes their suffering | The Seattle Times
Rx Digital Marketing
Novartis taps growing Biofourmis for digital heart failure project | Fierce Biotech
Fundación Signo on X: "https://t.co/2eMh5pMGvt" / X
